Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Clinical safety of tbo-filgrastim, a short-acting human granulocyte colony-stimulating factor | SpringerLink
FDA approves Teva's biosimilar for neutropaenia in cancer patients - PMLiVE
PDF] Multidisciplinary approach to evaluating immunogenicity of biosimilars: lessons learnt and open questions based on 10 years' experience of the European Union regulatory pathway | Semantic Scholar
Key concepts and critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation
Comparison of PBSC mobilized by either the biosimilar XM02... | Download Scientific Diagram
Teva receives FDA approval for filgrastim in the US